Plecanatide decreases severity of abdominal pain, bloating in IBS-C
Click Here to Manage Email Alerts
CHARLOTTE, N.C. — Once daily plecanatide decreased symptom severity among patients with irritable bowel syndrome-constipation and severe abdominal pain and bloating, according to a poster presented at the ACG Annual Scientific Meeting.
“The objective of this analysis was to evaluate the efficacy of plecanatide for improving severe abdominal pain and/or severe bloating in patients with IBS-C,” Gregory S. Sayuk, MD, MPH, associate professor of gastroenterology at Washington University School of Medicine, told Healio.
Sayuk and colleagues pooled and analyzed data from two randomized, phase 3 trials of adults with IBS-C treated for 12 weeks with plecanatide 3 mg once daily or placebo. Patients rated abdominal pain and bloating on an 11-point scale, with scores of 8 or higher indicating severe abdominal pain or bloating. Researchers defined response as at least 30% improvement from baseline in symptom scores.
Of 1,453 patients analyzed (plecanatide, n = 724; placebo, n = 729), 19.6% reported severe abdominal pain, 21.4% reported severe bloating and 16% reported both. Compared with placebo, a “significantly greater” percentage of patients treated with plecanatide who reported severe abdominal pain (19.2% vs. 33.8%), bloating (18.6% vs. 33.5%) or both (14% vs. 26.9%) at baseline responded at week 12.
Further, researchers noted changes in symptoms from baseline to week 12 were “strongly and positively” correlated in the overall population and among those with severe pain and bloating at baseline.
“The observed parallel, which correlated improvement in both abdominal pain and bloating, provides indirect evidence of an associated pathogenesis of these IBS-C symptoms,” Sayuk said. “Results from this poster may help better inform health care providers as they provide care and improved outcomes for patients with IBS-C experiencing abdominal pain and bloating.”
They added, “Future research should continue to evaluate efficacy of plecanatide as a treatment for patients with IBS-C.”
Collapse
Sayuk GS, et al. Poster B0261: Plecanatide improves severe abdominal pain and severe bloating in individuals
with irritable bowel syndrome with constipation: A pooled analysis of two phase 3 trials. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).
Read more about
Click Here to Manage Email Alerts